HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition.

Abstract
Western style diets and lifestyles are associated with increasing rates of obesity, diabetes and insulin resistance. Higher circulating insulin levels may modulate cell proliferation and apoptosis either directly or indirectly by increasing the bioactivity of IGF-I and decreasing the bioactivity of some of its binding proteins. The objective of this study was to determine the association of increasing levels of serum C-peptide, a biomarker of pancreatic insulin secretion, and IGF binding proteins (IGFBP) -1 and -2 with colorectal cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), a large cohort involving 10 Western European countries. A total of 1,078 colorectal cancer cases were matched (age, date of blood donation, fasting status, gender, study center) to an equal number of control subjects. Relative cancer risks were estimated using conditional logistic regression models. Serum C-peptide concentration was positively associated with an increased colorectal cancer risk for the highest versus the lowest quintile (OR=1.56, 95% CI=1.16-2.09, p(trend)<0.01), which was slightly attenuated after adjustment for BMI and physical activity (OR=1.37, 95% CI=1.00-1.88, p(trend)=0.10). When stratified by anatomical site, the cancer risk was stronger in the colon (OR=1.67, 95% CI=1.14-2.46, p(trend)<0.01) than in the rectum (OR=1.42, 95% CI=0.90-2.25, p(trend)=0.35). The cancer risk estimates were not heterogeneous by gender or fasting status. No clear colorectal cancer risk associations were observed for IGFBP-1 or -2. This large prospective study confirms that hyperinsulinemia, as determined by C-peptide levels, is associated with an increased colorectal cancer risk.
AuthorsMazda Jenab, Elio Riboli, Rebecca J Cleveland, Teresa Norat, Sabina Rinaldi, Alexandra Nieters, Carine Biessy, Ann Tjønneland, Anja Olsen, Kim Overvad, Henning Grønbaek, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Jakob Linseisen, Heiner Boeing, Tobias Pischon, Dimitrios Trichopoulos, Eleni Oikonomou, Antonia Trichopoulou, Salvatore Panico, Paolo Vineis, Franco Berrino, Rosario Tumino, Giovanna Masala, Petra H Peters, Carla H van Gils, H Bas Bueno-de-Mesquita, Marga C Ocké, Eiliv Lund, Michelle A Mendez, María José Tormo, Aurelio Barricarte, Carmen Martínez-García, Miren Dorronsoro, José Ramón Quirós, Göran Hallmans, Richard Palmqvist, Göran Berglund, Jonas Manjer, Timothy Key, Naomi E Allen, Sheila Bingham, Kay-Tee Khaw, Anne Cust, Rudolf Kaaks
JournalInternational journal of cancer (Int J Cancer) Vol. 121 Issue 2 Pg. 368-76 (Jul 15 2007) ISSN: 0020-7136 [Print] United States
PMID17372899 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright(c) 2007 Wiley-Liss, Inc.
Chemical References
  • C-Peptide
  • Insulin-Like Growth Factor Binding Protein 1
  • Insulin-Like Growth Factor Binding Protein 2
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Body Mass Index
  • C-Peptide (blood)
  • Case-Control Studies
  • Europe
  • Female
  • Follow-Up Studies
  • Humans
  • Insulin-Like Growth Factor Binding Protein 1 (blood)
  • Insulin-Like Growth Factor Binding Protein 2 (blood)
  • Logistic Models
  • Male
  • Middle Aged
  • Prospective Studies
  • Rectal Neoplasms (blood, diagnosis)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: